相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Characterization of V36C, a Novel Amino Acid Substitution Conferring Hepatitis C Virus (HCV) Resistance to Telaprevir, a Potent Peptidomimetic Inhibitor of HCV Protease
Laetitia Barbotte et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs)
Tara L. Kieffer et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors
Robert Chase et al.
ANTIVIRAL RESEARCH (2009)
Hepatitis C Virus Drug Resistance and Immune-Driven Adaptations: Relevance to New Antiviral Therapy
Silvana Gaudieri et al.
HEPATOLOGY (2009)
Characterization of Resistance to the Protease Inhibitor Boceprevir in Hepatitis C Virus-Infected Patients
Simone Susser et al.
HEPATOLOGY (2009)
Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP-424), pegylated interferon and ribavirin for 12 weeks
Fumitaka Suzuki et al.
HEPATOLOGY RESEARCH (2009)
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
Dongliang Ge et al.
NATURE (2009)
IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy
Vijayaprakash Suppiah et al.
NATURE GENETICS (2009)
Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C
Yasuhito Tanaka et al.
NATURE GENETICS (2009)
Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection
Christophe Hezode et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection
John G. McHutchison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Characterization of resistance mutations against HCV ketoamide protease inhibitors
Xiao Tong et al.
ANTIVIRAL RESEARCH (2008)
Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy
Ahmed El-Shamy et al.
HEPATOLOGY (2008)
Naturally Occurring Dominant Resistance Mutations to Hepatitis C Virus Protease and Polymerase Inhibitors in Treatment-Naive Patients
Thomas Kuntzen et al.
HEPATOLOGY (2008)
Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3•4A protease inhibitors in treatment-naive subjects
Doug J. Bartels et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient
Maria Cubero et al.
VIROLOGY (2008)
Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus
Christoph Welsch et al.
GENOME BIOLOGY (2008)
Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system
Yupeng He et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Phenotypic characterization of resistant Val(36) variants of hepatitis C virus NS3-4A serine protease
Yi Zhou et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients
Tara L. Kieffer et al.
HEPATOLOGY (2007)
Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C
Nicole Forestier et al.
HEPATOLOGY (2007)
Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir
Christoph Sarrazin et al.
GASTROENTEROLOGY (2007)
Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: Amino acid substitutions in the core region and low-density lipoprotein cholesterol levels
Norio Akuta et al.
JOURNAL OF HEPATOLOGY (2007)
Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034
Xiao Tong et al.
ANTIVIRAL RESEARCH (2006)
Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor - Reduced rna replication fitness and partial rescue by second-site mutations
MK Yi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype1b and high viral load
N Akuta et al.
JOURNAL OF MEDICAL VIROLOGY (2006)
Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro
HM Mo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061 - Structural analysis indicates different resistance mechanisms
C Lin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C -: A randomized study of treatment duration and ribavirin dose
SJ Hadziyannis et al.
ANNALS OF INTERNAL MEDICINE (2004)
Care of patients with hepatitis C and HIV co-infection
V Soriano et al.
AIDS (2004)
Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro
LJ Lu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
分享论文
